Maternal Serum Alpha-fetoprotein Level May Predict the Presence of Morbid Adherent Placenta
NCT ID: NCT04082507
Last Updated: 2019-09-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
150 participants
OBSERVATIONAL
2017-01-01
2019-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Creatine Kinase Versus 3D Doppler for Antenatal Diagnosis of Abnormal Adherent Placenta.
NCT03224780
Morbidly Adherent Placenta, Diagnosis and Proper Management
NCT05307016
Pulmonary Artery Doppler and Neonatal Outcome in Placenta Accreta Spectrum Patients
NCT04911322
3D Placental Volume in Placenta Accreta
NCT06755047
Evaluating Placental Thickness and Thickness of Uterine Muscle at Placenta Attachment in Prediction of Postpartum Blood Loss in Placenta Accreta
NCT06351969
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Non_adherent plcenta
placenta separated within 15 minutes after delivery of fetus
No interventions assigned to this group
Adherent placenta
placenta dosenot separated within 15 minutes after delivery of fetus
Serum alpha-fetoproteine
Midtrimesteric serum alpha-fetoprotein mesurment with 2D US and 3D power Doppler with MS US scan .
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Serum alpha-fetoproteine
Midtrimesteric serum alpha-fetoprotein mesurment with 2D US and 3D power Doppler with MS US scan .
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* plcenta previa covering the scar of previous caesarean section as diagnosed by 2DU/S
* Gestational age from 28wks to full term
Exclusion Criteria
* pregnant women with ovarian swelling
* pregnant women with medical disease
20 Years
39 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
rasha medhat abdul-hady
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
rasha medhat abdul-hady
Lecturer of obstetrics and gynecology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ain shams university maternity hospital
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AFP_AP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.